Molecular Devices Receives Broad Patent Covering its SPECTRAmax Microplate Readers
"We are very pleased to have this patent issued, as we believe it covers the critical combination of features that make these products so successful," stated Joseph D. Keegan, Ph.D., President and Chief Executive Officer of Molecular Devices. "In addition, the award of the patent demonstrates our strong commitment to developing innovative, first-of-a-kind products."
Using the covered microplate reader systems, pharmaceutical, biotechnology, and academic research scientists can analyze up to 384 samples in the UV, visible, and near-infrared spectrum in as little as 16 seconds with no compromise on performance or capabilities. Common biological applications include automated ELISA, protein, DNA, endotoxin, and enzyme assays.
The patent protects the unmatched flexibility and sensitivity of the products, due to the combination of a very bright flashlamp and tunable monochromators for microplate spectrophotometry. The monochromator enables simple assay optimization and eliminates the need to replace filters, as is required in traditional readers.
Molecular Devices Corporation is a leading developer of high-performance, bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Molecular Devices' systems enable pharmaceutical and biotechnology companies to leverage advances in genomics and combinatorial chemistry by facilitating the high throughput and cost effective identification and evaluation of drug candidates. Molecular Devices' instrument systems are based on its advanced core technologies which integrate its expertise in engineering, molecular and cell biology and chemistry and are fundamental tools for drug discovery and life sciences research.
This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intent" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Molecular Devices Corporation to differ materially from those indicated by these forward-looking statements, including, among others, risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 1999, its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2000 and its Registration Statement on Form S-4, as amended as of July 17, 2000, and definitive proxy statement filed in connection with the acquisition of LJL BioSystems, Inc.